Corbus Pharmaceuticals (CRBP) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

CRBP Stock Forecast

Corbus Pharmaceuticals stock forecast is as follows: an average price target of $57.80 (represents a 337.22% upside from CRBP’s last price of $13.22) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.

CRBP Price Target

The average price target for Corbus Pharmaceuticals (CRBP) is $57.80 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $80.00 to $35.00. This represents a potential 337.22% upside from CRBP's last price of $13.22.

CRBP Analyst Ratings

Buy

According to 8 Wall Street analysts, Corbus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CRBP stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Corbus Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Dec 02, 2024	Biren Amin	Piper Sandler	$35.00	$17.82	96.41%	164.75%
Oct 21, 2024	Jeff Jones	Oppenheimer	$60.00	$18.41	225.91%	353.86%
Sep 20, 2024	Kalpit Patel	B.Riley Financial	$40.00	$19.51	105.02%	202.57%
Sep 13, 2024	Graig Suvannavejh	Mizuho Securities	$74.00	$51.58	43.47%	459.76%
Aug 07, 2024	Jeff Jones	Oppenheimer	$88.00	$48.30	82.19%	565.66%
Jul 22, 2024	Andres Maldonado	H.C. Wainwright	$80.00	$58.00	37.93%	505.14%
Jun 11, 2024	Brian Abrahams	RBC Capital	$82.00	$43.87	86.92%	520.27%
Jun 03, 2024	Jeff Jones	Oppenheimer	$80.00	$42.80	86.92%	505.14%
May 20, 2024	Brian Abrahams	RBC Capital	$77.00	$45.00	71.11%	482.45%
Mar 06, 2024	Maury Raycroft	Jefferies	$46.00	$33.58	36.99%	247.96%

The latest Corbus Pharmaceuticals stock forecast, released on Dec 02, 2024 by Biren Amin from Piper Sandler, set a price target of $35.00, which represents a 96.41% increase from the stock price at the time of the forecast ($17.82), and a 164.75% increase from CRBP last price ($13.22).

Corbus Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	1	3	10
Avg Price Target	$35.00	$45.00	$66.20
Last Closing Price	$13.22	$13.22	$13.22
Upside/Downside	164.75%	240.39%	400.76%

In the current month, the average price target of Corbus Pharmaceuticals stock is $35.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 164.75% increase as opposed to Corbus Pharmaceuticals's last price of $13.22. This month's average price target is down -22.22% compared to last quarter, and down -47.13% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Dec 02, 2024	Piper Sandler		Overweight	Initialise
Oct 21, 2024	Oppenheimer	Outperform	Outperform	Hold
Sep 23, 2024	Oppenheimer	Buy	Buy	Hold
Sep 23, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 20, 2024	Wedbush	Outperform	Outperform	Hold
Sep 20, 2024	B. Riley Securities	Buy	Buy	Hold
Sep 20, 2024	B. Riley	Buy	Buy	Hold
Sep 20, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 07, 2024	Oppenheimer	Outperform	Outperform	Hold
Jul 29, 2024	Wedbush		Outperform	Initialise
Jun 25, 2024	B. Riley		Buy	Initialise
Jun 11, 2024	RBC Capital	Outperform	Outperform	Hold
Jun 03, 2024	Oppenheimer	Outperform	Outperform	Hold
May 20, 2024	RBC Capital	Outperform	Outperform	Hold
May 13, 2024	RBC Capital		Outperform	Initialise
Mar 06, 2024	Jefferies		Buy	Upgrade
May 10, 2023	Oppenheimer		Outperform	Upgrade

Corbus Pharmaceuticals's last stock rating was published by Piper Sandler on Dec 02, 2024. The company Initialise its CRBP rating from "null" to "Overweight".

Corbus Pharmaceuticals Financial Forecast

Corbus Pharmaceuticals Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Sep 15
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$-233.88K	$97.32K	$136.56K	$647.82K	$658.20K	$1.23M	$286.35K	$1.76M	$2.57M	$2.59M	$29.09M	$1.89M	$950.44K	$1.29M	$396.60K	$170.45K
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$200.00K	$150.00K	$347.50K	$978.00K	$885.50K	$952.00K	$1.49M	$3.24M	$3.39M	$2.41M	$3.69M	$1.84M	$12.50M	$2.73M	$633.63K	$1.29M	$396.60K	$227.27K
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$200.00K	$150.00K	$347.50K	$978.00K	$885.50K	$952.00K	$1.49M	$3.24M	$3.39M	$2.41M	$3.69M	$1.84M	$12.50M	$2.73M	$760.35K	$1.55M	$475.92K	$272.73K
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$200.00K	$150.00K	$347.50K	$978.00K	$885.50K	$952.00K	$1.49M	$3.24M	$3.39M	$2.41M	$3.69M	$1.84M	$12.50M	$2.73M	$506.90K	$1.03M	$317.28K	$181.82K
# Analysts	-	-	-	-	-	-	-	-	-	-	-	7	8	13	8	8	9	13	8	8	9	12	7	7	8	16	8	16	11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.67%	0.10%	0.15%	0.68%	0.44%	0.38%	0.08%	0.73%	0.70%	1.41%	2.33%	0.69%	1.50%	1.00%	1.00%	0.75%

Corbus Pharmaceuticals's average Quarter revenue forecast for Mar 22 based on 8 analysts is $150.00K, with a low forecast of $150.00K, and a high forecast of $150.00K. CRBP's average Quarter revenue forecast represents a -164.14% decrease compared to the company's last Quarter revenue of $-233.88K (Dec 21).

Corbus Pharmaceuticals EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Sep 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	7	8	13	8	8	9	13	8	8	9	12	7	7	8	16	8	16	11
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-1.76M	$-7.88M	$-12.09M	$-1.76M	$-16.72M	$-15.64M	$-8.18M	$-34.10M	$-37.64M	$-29.20M	$-26.18M	$-20.51M	$2.45M	$-25.99M	$-11.61M	$-7.43M	$-2.87M	$-2.24M
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$-40.00K	$-7.88M	$-69.50K	$-195.60K	$-177.10K	$-16.68M	$-298.08K	$-647.44K	$-678.17K	$-27.01M	$-737.08K	$-367.64K	$-2.50M	$-11.65M	$-6.39M	$-7.43M	$-2.87M	$-2.80M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$-40.00K	$-6.30M	$-69.50K	$-195.60K	$-177.10K	$-13.35M	$-298.08K	$-647.44K	$-678.17K	$-21.61M	$-737.08K	$-367.64K	$-2.50M	$-9.32M	$-5.11M	$-5.95M	$-2.29M	$-2.24M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$-40.00K	$-9.46M	$-69.50K	$-195.60K	$-177.10K	$-20.02M	$-298.08K	$-647.44K	$-678.17K	$-32.41M	$-737.08K	$-367.64K	$-2.50M	$-13.98M	$-7.66M	$-8.92M	$-3.44M	$-3.36M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	44.00%	1.00%	173.98%	8.99%	94.40%	0.94%	27.45%	52.66%	55.51%	1.08%	35.51%	55.78%	-0.98%	2.23%	1.82%	1.00%	1.00%	0.80%

7 analysts predict CRBP's average Quarter EBITDA for Sep 19 to be $-367.64K, with a high of $-367.64K and a low of $-367.64K. This is -114.99% lower than Corbus Pharmaceuticals's previous annual EBITDA (Jun 19) of $2.45M.

Corbus Pharmaceuticals Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Sep 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	7	8	13	8	8	9	13	8	8	9	12	7	7	8	16	8	16	11
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-24.86M	$-11.08M	$-12.35M	$-2.18M	$-17.14M	$-16.07M	$-8.61M	$-34.90M	$-38.11M	$-29.66M	$-26.58M	$-20.79M	$2.15M	$-26.23M	$-11.70M	$-7.47M	$-2.89M	$-2.25M
Avg Forecast	$-20.73M	$-18.85M	$-17.23M	$-15.74M	$-21.72M	$-20.30M	$-19.06M	$-18.17M	$-14.91M	$-11.44M	$-13.13M	$-19.90M	$-9.44M	$-37.30M	$-38.13M	$-39.13M	$-17.14M	$-83.56M	$-134.63M	$-124.35M	$-27.43M	$-118.71M	$-126.67M	$-54.71M	$-11.76M	$-6.43M	$-7.47M	$-2.89M	$-2.82M
High Forecast	$-20.73M	$-18.85M	$-17.23M	$-15.74M	$-21.72M	$-20.30M	$-19.06M	$-9.26M	$-11.70M	$-11.44M	$-13.13M	$-19.90M	$-7.55M	$-37.30M	$-38.13M	$-39.13M	$-13.71M	$-83.56M	$-134.63M	$-124.35M	$-21.95M	$-118.71M	$-126.67M	$-54.71M	$-9.41M	$-5.15M	$-5.97M	$-2.31M	$-2.25M
Low Forecast	$-20.73M	$-18.85M	$-17.23M	$-15.74M	$-21.72M	$-20.30M	$-19.06M	$-35.49M	$-17.44M	$-11.44M	$-13.13M	$-19.90M	$-11.32M	$-37.30M	$-38.13M	$-39.13M	$-20.56M	$-83.56M	$-134.63M	$-124.35M	$-32.92M	$-118.71M	$-126.67M	$-54.71M	$-14.11M	$-7.72M	$-8.96M	$-3.47M	$-3.38M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	1.25%	1.17%	0.33%	0.06%	0.44%	0.94%	0.10%	0.26%	0.31%	1.08%	0.22%	0.16%	-0.04%	2.23%	1.82%	1.00%	1.00%	0.80%

Corbus Pharmaceuticals's average Quarter net income forecast for Sep 19 is $-126.67M, with a range of $-126.67M to $-126.67M. CRBP's average Quarter net income forecast represents a -5984.37% decrease compared to the company's last Quarter net income of $2.15M (Jun 19).

Corbus Pharmaceuticals SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Sep 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	7	8	13	8	8	9	13	8	8	9	12	7	7	8	16	8	16	11
SG&A	-	-	-	-	-	-	-	-	-	-	-	$4.84M	$5.23M	$4.23M	$5.28M	$5.57M	$5.34M	$5.36M	$7.68M	$7.74M	$7.70M	$6.28M	$5.53M	$5.21M	$6.62M	$3.05M	$2.38M	$1.11M	$790.58K
Avg Forecast	-	-	-	-	-	-	-	-	-	-	-	$1.32M	$991.61K	$2.30M	$6.47M	$5.85M	$6.29M	$9.85M	$21.40M	$22.42M	$15.94M	$24.36M	$12.15M	$82.67M	$18.06M	$4.19M	$8.55M	$2.62M	$1.50M
High Forecast	-	-	-	-	-	-	-	-	-	-	-	$1.32M	$991.61K	$2.30M	$6.47M	$5.85M	$6.29M	$9.85M	$21.40M	$22.42M	$15.94M	$24.36M	$12.15M	$82.67M	$18.06M	$5.03M	$10.26M	$3.15M	$1.80M
Low Forecast	-	-	-	-	-	-	-	-	-	-	-	$1.32M	$991.61K	$2.30M	$6.47M	$5.85M	$6.29M	$9.85M	$21.40M	$22.42M	$15.94M	$24.36M	$12.15M	$82.67M	$18.06M	$3.35M	$6.84M	$2.10M	$1.20M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	3.66%	5.28%	1.84%	0.82%	0.95%	0.85%	0.54%	0.36%	0.35%	0.48%	0.26%	0.46%	0.06%	0.37%	0.73%	0.28%	0.42%	0.53%

Corbus Pharmaceuticals's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CRBP last annual SG&A of $4.84M (Jun 22).

Corbus Pharmaceuticals EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Sep 15
# Analysts	-	-	-	-	-	-	-	-	-	-	-	7	8	13	8	8	9	13	8	8	9	12	7	7	8	16	8	16	11
EPS	-	-	-	-	-	-	-	-	-	-	-	$-5.95	$-2.66	$-2.96	$-0.52	$-4.42	$-4.14	$-2.96	$-12.79	$-15.47	$-12.84	$-12.33	$-9.65	$0.94	$-12.76	$-6.22	$-4.83	$-2.31	$-1.94
Avg Forecast	$-1.73	$-1.57	$-1.43	$-1.31	$-1.81	$-1.69	$-1.59	$-1.51	$-1.24	$-0.95	$-1.19	$-1.80	$-2.55	$-3.38	$-3.45	$-3.54	$-4.50	$-7.56	$-12.18	$-11.25	$-12.05	$-10.74	$-11.46	$-4.95	$-8.40	$-0.08	$-0.16	$-0.08	$-0.10
High Forecast	$-1.73	$-1.57	$-1.43	$-1.31	$-1.81	$-1.69	$-1.59	$-0.77	$-0.97	$-0.95	$-1.19	$-1.80	$-2.55	$-3.38	$-3.45	$-3.54	$-4.50	$-7.56	$-12.18	$-11.25	$-12.05	$-10.74	$-11.46	$-4.95	$-8.40	$-0.06	$-0.13	$-0.06	$-0.08
Low Forecast	$-1.73	$-1.57	$-1.43	$-1.31	$-1.81	$-1.69	$-1.59	$-2.95	$-1.45	$-0.95	$-1.19	$-1.80	$-2.55	$-3.38	$-3.45	$-3.54	$-4.50	$-7.56	$-12.18	$-11.25	$-12.05	$-10.74	$-11.46	$-4.95	$-8.40	$-0.09	$-0.19	$-0.10	$-0.12
Surprise %	-	-	-	-	-	-	-	-	-	-	-	3.31%	1.04%	0.88%	0.15%	1.25%	0.92%	0.39%	1.05%	1.38%	1.07%	1.15%	0.84%	-0.19%	1.52%	77.81%	30.18%	28.84%	19.45%

According to 7 Wall Street analysts, Corbus Pharmaceuticals's projected average Quarter EPS for Sep 19 is $-11.46, with a low estimate of $-11.46 and a high estimate of $-11.46. This represents a -1315.78% decrease compared to CRBP previous annual EPS of $0.94 (Jun 19).

Corbus Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
SPRO	Spero Therapeutics	$1.04	$10.00	861.54%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
AFMD	Affimed	$1.51	$7.50	396.69%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
CRBP	Corbus Pharmaceuticals	$14.29	$57.80	304.48%	Buy
ZURA	Zura Bio	$2.51	$10.00	298.41%	Buy
BCAB	BioAtla	$1.31	$5.00	281.68%	Buy
ANTX	AN2 Therapeutics	$1.34	$5.00	273.13%	Buy
ADVM	Adverum Bio	$5.23	$19.33	269.60%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
NXTC	NextCure	$0.90	$3.00	233.33%	Buy
CTMX	CytomX Therapeutics	$1.13	$3.47	207.08%	Buy
CUE	Cue Biopharma	$1.06	$3.00	183.02%	Buy
ASMB	Assembly Biosciences	$14.28	$35.50	148.60%	Buy
MREO	Mereo BioPharma Group	$3.40	$8.00	135.29%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
GLMD	Galmed Pharmaceuticals	$3.01	$5.00	66.11%	Buy
TRVI	Trevi Therapeutics	$4.50	$6.00	33.33%	Buy
KOD	Kodiak Sciences	$8.87	$11.00	24.01%	Buy

CRBP Forecast FAQ

Is Corbus Pharmaceuticals a good buy?

Yes, according to 8 Wall Street analysts, Corbus Pharmaceuticals (CRBP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 100.00% of CRBP's total ratings.

What is CRBP's price target?

Corbus Pharmaceuticals (CRBP) average price target is $57.8 with a range of $35 to $80, implying a 337.22% from its last price of $13.22. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Corbus Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for CRBP stock, the company can go up by 337.22% (from the last price of $13.22 to the average price target of $57.8), up by 505.14% based on the highest stock price target, and up by 164.75% based on the lowest stock price target.

Can Corbus Pharmaceuticals stock reach $20?

CRBP's average twelve months analyst stock price target of $57.8 supports the claim that Corbus Pharmaceuticals can reach $20 in the near future.

What is Corbus Pharmaceuticals's current price target trend?

1 Wall Street analyst forecast a $35 price target for Corbus Pharmaceuticals (CRBP) this month, up 164.75% from its last price of $13.22. Compared to the last 3 and 12 months, the average price target increased by 240.39% and increased by 400.76%, respectively.

What are Corbus Pharmaceuticals's analysts' financial forecasts?

Corbus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-79.249M (high $-70.346M, low $-96.573M), average SG&A $0 (high $0, low $0), and average EPS is $-6.596 (high $-5.855, low $-8.038). CRBP's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-72.542M (high $-72.542M, low $-72.542M), average SG&A $0 (high $0, low $0), and average EPS is $-6.038 (high $-6.038, low $-6.038).

Did the CRBP's actual financial results beat the analysts' financial forecasts?

Based on Corbus Pharmaceuticals's last annual report (Dec 2021), the company's revenue was $881.7K, which missed the average analysts forecast of $3.16M by -72.12%. Apple's EBITDA was $-56.268M, beating the average prediction of $-17.126M by 228.56%. The company's net income was $-35.204M, missing the average estimation of $-132M by -73.27%. Apple's SG&A was $20.43M, missing the average forecast of $20.91M by -2.32%. Lastly, the company's EPS was $-8.59, missing the average prediction of $-14.865 by -42.21%. In terms of the last quarterly report (Dec 2021), Corbus Pharmaceuticals's revenue was $-234K, missing the average analysts' forecast of $347.5K by -167.30%. The company's EBITDA was $-12.091M, beating the average prediction of $-69.499K by 17297.69%. Corbus Pharmaceuticals's net income was $-12.354M, missing the average estimation of $-37.305M by -66.88%. The company's SG&A was $4.23M, beating the average forecast of $2.3M by 84.34%. Lastly, the company's EPS was $-2.96, missing the average prediction of $-3.375 by -12.30%